戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as preceded by 2 hour of pulse-labeling with 5-bromodeoxyuridine.
2 ular proliferation, as assessed by uptake of 5-bromodeoxyuridine.
3 d cells and incorporated into genomic DNA as 5-bromodeoxyuridine.
4      S phase cells were labeled in vivo with 5-bromodeoxyuridine.
5 DNA in these glands with a different marker, 5-bromodeoxyuridine (5BrdU), resulted in the appearance
6 ivated cross-linking of a self-complementary 5-bromodeoxyuridine (5BrU)-substituted oligonucleotide w
7 elevations in numbers of cells incorporating 5'-bromodeoxyuridine, a marker of unscheduled DNA synthe
8 ife by using two cell cycle-specific labels: 5-bromodeoxyuridine, a thymidine analog that labels cell
9 i) hypersensitivity to the nucleoside analog 5-bromodeoxyuridine and (ii) retention of more uracil re
10 tion (types I and III) and incorporated more 5-bromodeoxyuridine and TUNEL staining compared with uns
11 l detection of a marker for DNA replication (5-bromodeoxyuridine) and several cell type-specific mark
12 rve-tracing techniques, birth-date labeling (5-bromodeoxyuridine), and electrophysiology were used to
13 naive CD4+ T cells were labeled ex vivo with 5-bromodeoxyuridine as well as stained directly for Ki67
14 nd and those that occur after treatment with 5-bromodeoxyuridine, as these mutations are also drastic
15  identification, RPE cells were labeled with 5-bromodeoxyuridine, before intraocular transplantation.
16                                        Using 5'-bromodeoxyuridine birth dating we established that mo
17                        Eosinophil levels and 5'-bromodeoxyuridine (BrdU) incorporation were examined
18 ymal cells as judged by the incorporation of 5'-bromodeoxyuridine (BrdU).
19     We have determined the in vivo effect of 5-bromodeoxyuridine (BrdU) administered to mice in the d
20 ilis chromosome with the nucleotide analogue 5-bromodeoxyuridine (BrdU) and for subcellular visualiza
21                 HeLa cells were labeled with 5-bromodeoxyuridine (BrdU) at different times of S phase
22 quently we administered a cell cycle marker, 5-bromodeoxyuridine (BrdU) at early, middle or late peri
23                 Using this method, we detect 5-bromodeoxyuridine (BrdU) incorporated by Saccharomyces
24 oximal tubular cells was detected by in vivo 5-bromodeoxyuridine (BrdU) incorporation on day 3.
25  the pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if
26                                              5-bromodeoxyuridine (BrdU) incorporation was used to exa
27 e kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation.
28                                              5-Bromodeoxyuridine (BrdU) labeling, proliferating cell
29 beling (TUNEL) to detect the dying cells and 5-bromodeoxyuridine (BrdU) to label newly generated cell
30                             Forty-eight hour 5-bromodeoxyuridine (BrdU) uptake (used as an index of p
31  48 h later by intraperitoneal injections of 5-bromodeoxyuridine (BrdU), a marker for cell proliferat
32 reased proliferative activity assessed using 5-bromodeoxyuridine (BrdU), Ki-67, and c-Myc relative to
33 o retain labels such as the thymidine analog 5-bromodeoxyuridine (BrdU).
34  were identified by nuclear incorporation of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).
35 n cortex, using markers for DNA replication (5-bromodeoxyuridine; BrdU) and progressive neuronal diff
36 s and compared with that found using in vivo 5-bromodeoxyuridine (BrdUrd) labeling in formalin-fixed
37 ine perchlorate (DiI)], birth date labeling (5-bromodeoxyuridine), confocal microscopy, and electroph
38 followed by Hi-C and then the destruction of 5-bromodeoxyuridine-containing strands via Hoechst/ultra
39                                         Anti-5-bromodeoxyuridine immunolabeling revealed a significan
40 o myocardium induced DNA synthesis, shown by 5'-bromodeoxyuridine incorporation, and accumulation in
41  elevated proliferation rates as assessed by 5-bromodeoxyuridine incorporation and cell-cycle analysi
42                                  Analysis of 5-bromodeoxyuridine incorporation by these cells indicat
43  sustained in mitogen-restimulated myocytes, 5-bromodeoxyuridine incorporation experiments in serum-s
44                                  Analysis of 5-bromodeoxyuridine incorporation into DNA following inf
45 issociated cushion cells displayed increased 5-bromodeoxyuridine incorporation when infected with Q79
46 sing independent parameters of regeneration, 5-bromodeoxyuridine incorporation, proliferating cell nu
47 h the entry of cells into the cell cycle and 5-bromodeoxyuridine incorporation.
48 uated by hematoxylin and eosin histology and 5-bromodeoxyuridine incorporation.
49 ne, is detected on days 2 and 3 by increased 5-bromodeoxyuridine incorporation.
50                           A mild increase in 5-bromodeoxyuridine labeling is observed in peripheral a
51                              Comparison with 5-bromodeoxyuridine labeling of cells in S phase indicat
52  and ES cell-derived cardiomyocytes based on 5-bromodeoxyuridine labeling was similar, and immunocyto
53                         However, pulse-chase 5-bromodeoxyuridine-labeling assay revealed that the sen
54 ealed a 7-fold increase in the percentage of 5-bromodeoxyuridine-positive cells and a 20-40-fold incr
55 , mtDNA (labeled with the thymidine analogue 5-bromodeoxyuridine) remained distinctly localized to on
56 nd dopaminergic-like neurons - using chronic 5-Bromodeoxyuridine treatment and validated our findings
57                                              5-Bromodeoxyuridine was used to label dividing cells.